Entecavir NDC 42806-659

NDC codes

FDA NDC Directory

Product NDC (as listed)42806-659Labeler and product segments. Claims need a package NDC.

Product NDC at billing width42806-0659Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
42806-659-30	42806065930	30 TABLET in 1 BOTTLE, PLASTIC (42806-659-30)Marketed from Jun 2, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Entecavir
Generic name (nonproprietary): entecavir
Active ingredients: Entecavir — 1 mg/1
Dosage form: Tablet
Route: Oral
Labeler: EPIC PHARMA, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212126
Marketing start: Jun 2, 2020
Listing expires: Dec 31, 2027
Other FDA classes: Nucleoside Analog (EXT)Nucleoside Reverse Transcriptase Inhibitors (Mechanism)
Identifiers: Product ID 42806-659_db290579-c9e1-44be-b03c-ad8a7efe5ce1SPL ID db290579-c9e1-44be-b03c-ad8a7efe5ce1SPL set ID af4f47e2-f556-40f2-a0fd-ff81e9f27429RxCUI 485434, 485436UNII 5968Y6H45MUPC 0342806658307, 0342806659304
Pharmacologic class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N442806065930 followed by a unit qualifier and the quantity

Package 42806-0659-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 15, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Entecavir is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. (1)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212126

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212126
Product	Strength	Form · route	Labeler	Product NDC
Entecavir	Entecavir .5 mg/1	TabletOral	EPIC PHARMA, LLC	42806-658